<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/548CBC65-B8D1-4BAD-B74D-0DB7DFA00ED4"><gtr:id>548CBC65-B8D1-4BAD-B74D-0DB7DFA00ED4</gtr:id><gtr:name>University of Tasmania</gtr:name><gtr:address><gtr:line1>Hobart Campus</gtr:line1><gtr:line2>GPO Box 252</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/548CBC65-B8D1-4BAD-B74D-0DB7DFA00ED4"><gtr:id>548CBC65-B8D1-4BAD-B74D-0DB7DFA00ED4</gtr:id><gtr:name>University of Tasmania</gtr:name><gtr:address><gtr:line1>Hobart Campus</gtr:line1><gtr:line2>GPO Box 252</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A755A4D8-87BD-4F03-8741-278598939082"><gtr:id>A755A4D8-87BD-4F03-8741-278598939082</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Corris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CBD881ED-F4A5-4F26-BE9A-E89D3F8E0F4F"><gtr:id>CBD881ED-F4A5-4F26-BE9A-E89D3F8E0F4F</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/877A1CCD-0D0C-4AD5-A915-CB6DEE79C7BF"><gtr:id>877A1CCD-0D0C-4AD5-A915-CB6DEE79C7BF</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Dark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AE6D10A2-CE96-4CD3-9028-D1576E34E910"><gtr:id>AE6D10A2-CE96-4CD3-9028-D1576E34E910</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7AC202D8-9214-4092-8F97-5233950E75D4"><gtr:id>7AC202D8-9214-4092-8F97-5233950E75D4</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Lordan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500705"><gtr:id>94B21ADF-98B6-44F0-9CDF-780E1C47739D</gtr:id><gtr:title>The effect of macrolide therapy on sub-clinical infection and inflammation in human lung transplantation.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500705</gtr:grantReference><gtr:abstractText>For many chronic lung diseases, such as cystic fibrosis in young people, lung transplantation can be the only present treatment for advanced disease. This can extend life expectancy and quality, and allows resumption of day to day activities, but chronic rejection is a major problem. 

We will carry out research into how small amounts of infection, which do not cause immediate clinical problems, might cause subsequent chronic rejection. This has previously not been considered significant, and therefore has not been studied. This area of research has been chosen because it is a strength of respiratory medicine in the UK. The Freeman Hospital is one of the worlds largest transplant centres, making the work feasible. The question of why lung transplants develop chronic rejection is of national and international importance.

To do our work we will be using very sensitive molecular methods to quantify low levels of infection, to see if there is evidence to suggest that this may cause inflammation and scarring of the airways. We believe that this causes progressive shortness of breath and chronic transplant rejection.

New antibiotic therapies have been used in chronic rejection and this seems to help some people, but no one knows how this works. We will perform a formal scientific study of this approach to improve the available evidence. We will also perform experiments with lung samples from transplant patients that aim to investigate potential mechanisms, and why some people do well but others do not. To allow these experiments we will grow transplant cells from small samples to give the larger numbers of cells needed. All of our work will be done using human samples because these are the most appropriate for our research.

It is expected that our results will show that even low levels of infection are a problem to lung transplant patients and that antibiotic treatment helps this. This would change how chronic rejection is treated and we think this may help to protect transplanted lungs and extend life expectancy.</gtr:abstractText><gtr:technicalSummary>Introduction 
Five year mortality following lung transplantation is 50%, with chronic rejection, manifested functionally by bronchiolitis obliterans syndrome (BOS), the major cause of death. Current treatments have little impact on BOS, but we have recently shown that an open trial of the macrolide antibiotic azithromycin led to a clinically significant gain in lung function. The mechanisms for this improvement are not known.

Hypothesis
Sub-clinical airway infection and inflammation are key precursors of BOS. Macrolide antibiotics disrupt infection and are anti-inflammatory, leading to clinical benefit.

Methods
A longitudinal study of infection, airway inflammation and remodeling in lung transplantation, The effect of azithromycin therapy will be tested in a placebo controlled, parallel group design. Ex-vivo mechanistic studies will be made in primary bronchial epithelial cells from the same patients. All the proposed methods and the ability to recruit the required patient cohort are available to our laboratory.

Significance
This study will immediately impact on patient management.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>526603</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Tasmania</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Menzies Institute for Medical Research</gtr:department><gtr:description>Engagement with Menzies Institute Australia</gtr:description><gtr:id>B20DAD48-1AF3-4101-9A3A-86FDD9B1EE6F</gtr:id><gtr:impact>Honorary appointment with the Menzies Research Institute, University of Tasmania [Principal Research Fellow]

In 2011 the overall research collaboration at the University of Tasmania, of which this is a part, was awarded A$2.5 million over 5 years as a National Health &amp;amp; Medical Research Council Centre of Research Excellence. 

Output has also been papers:

1.Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH. Respir Res. 2011 Oct 5;12:130.

2. Infection and remodelling: a 21st century model of bronchiectasis? Ward C, Rydell-T&amp;ouml;rm&amp;auml;nen K, Westergren-Thorsson G, Eriksson LT, Walters H.
Eur Respir J. 2011 Oct;38(4):758-60. No abstract available. 

3.Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Wen Y, Reid DW, Zhang D, Ward C, Wood-Baker R, Walters EH. Int J Chron Obstruct Pulmon Dis. 2010 Oct 5;5:327-34.

4.Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Sohal SS, Reid D, Soltani A, Ward C, Weston S, Muller HK, Wood-Baker R, Walters EH. Respirology. 2010 Aug;15(6):930-8. Epub 2010 Jul 12.

5.Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, Walters EH. Respirology. 2008 Nov;13(6):799-809.

6.Angiogenesis: a potentially critical part of remodelling in chronic airway diseases?
Walters EH, Reid D, Soltani A, Ward C. Pharmacol Ther. 2008 Apr;118(1):128-37. Epub 2008 Feb 15. Review.

7.Vascular remodelling in asthma. Walters EH, Soltani A, Reid DW, Ward C.
Curr Opin Allergy Clin Immunol. 2008 Feb;8(1):39-43. Review.

8.Innate immune activation in neutrophilic asthma. Walters EH, Wood-Baker R, Reid DE, Ward C. Thorax. 2008 Jan;63(1):88-9. No abstract available. 

9.Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. Walters EH, Reid DW, Johns DP, Ward C. Eur Respir J. 2007 Sep;30(3):574-88. Review.

10.Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction. Khor YH, Feltis BN, Reid DW, Ward C, Johns DP, Wood-Baker R, Walters EH. Clin Exp Allergy. 2007 Aug;37(8):1189-98.

11.Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Feltis BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH.
Thorax. 2007 Apr;62(4):314-9. Epub 2006 Nov 14.

12.Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Feltis BN, Wignarajah D, Zheng L, Ward C, Reid D, Harding R, Walters EH. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1201-7. Epub 2006 Mar 9.</gtr:impact><gtr:outcomeId>cCqQg2z1tCn-1</gtr:outcomeId><gtr:partnerContribution>Publications (ten papers)</gtr:partnerContribution><gtr:piContribution>Expertise in cellular mechanisms involved in airway remodelling in chronic lung disease.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>An aerodigestive approach to lung disease</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FC891BFD-2CD0-44CF-8CF1-0C2E8C27CC41</gtr:id><gtr:impact>Our work has led others to consider non alloimmune injury in the lung including reflux and aspiration</gtr:impact><gtr:outcomeId>bFE8VooHssp</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Education on treatment for lung rejection</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>4131959C-FEA7-4DAB-9AB8-82A4C4DB4C3E</gtr:id><gtr:impact>Treatment options for lung transplant rejection have been limited. The understanding that macrolide therapy may have a role is important in guiding thinking and treatment regarding this important clinical issue. (Results of trial awaited).</gtr:impact><gtr:outcomeId>D72209F2995</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We hypothesised that azithromycin therapy is superior to placebo in patients with BOS. We tested this by conducting a prospective, single-centre, randomised double blind placebo controlled study funded by the MRC. The primary outcome was change in FEV1 from baseline to 12 weeks.</gtr:description><gtr:id>D27E1EA8-E01D-4607-8F44-9C96761E76E8</gtr:id><gtr:impact>Our understanding is that this is the only randomised placebo controlled trial of azithromycin therapy in patients who have developed BOS. Azithromycin was superior compared to placebo treatment. This therefore represents an important piece of evidence in support of clinical practice worldwide.</gtr:impact><gtr:outcomeId>sB56Ly79DWr</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Azithromycin therapy in Bronchiolitis Obliterans Syndrome (BOS) post lung transplantation.</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000485-36/GB</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F73D4D63-1B5F-47FE-A6E3-6333C10A13B5</gtr:id><gtr:title>Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects?</gtr:title><gtr:parentPublicationTitle>Expert opinion on investigational drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68394ce17788125efc5db3736789d708"><gtr:id>68394ce17788125efc5db3736789d708</gtr:id><gtr:otherNames>Murphy DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1354-3784</gtr:issn><gtr:outcomeId>piPMv9uEnLB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9DB4ED2-E154-49F4-B826-95214EC3A29D</gtr:id><gtr:title>Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bf5c6b77858a45127cf5422f70c109"><gtr:id>d1bf5c6b77858a45127cf5422f70c109</gtr:id><gtr:otherNames>Robertson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>By6eiehrMFS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>018F6396-C288-4642-B5C8-4A940850F256</gtr:id><gtr:title>Non-cystic fibrosis bronchiectasis.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f64f39cc55653d211eaffe32e196558a"><gtr:id>f64f39cc55653d211eaffe32e196558a</gtr:id><gtr:otherNames>McDonnell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_13477_27_23728208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5AC5A7E-89D0-4AAE-8F55-EA5980178700</gtr:id><gtr:title>Ceramide and cystic fibrosis lung disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4da8d21edac913ada1d3df758b27436"><gtr:id>d4da8d21edac913ada1d3df758b27436</gtr:id><gtr:otherNames>Brodlie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>mX8ra91u54c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64C6DABB-1C75-4AD5-AE4B-4776445C3133</gtr:id><gtr:title>Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells.</gtr:title><gtr:parentPublicationTitle>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68394ce17788125efc5db3736789d708"><gtr:id>68394ce17788125efc5db3736789d708</gtr:id><gtr:otherNames>Murphy DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1053-2498</gtr:issn><gtr:outcomeId>031BC9ABA34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61D521A2-981D-4B9C-B178-1754AD434825</gtr:id><gtr:title>Raised interleukin-17 is immunolocalised to neutrophils in cystic fibrosis lung disease.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4da8d21edac913ada1d3df758b27436"><gtr:id>d4da8d21edac913ada1d3df758b27436</gtr:id><gtr:otherNames>Brodlie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>ctNF8jM2j3z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CD78092-903B-4855-9940-FFA67ABC872E</gtr:id><gtr:title>Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>BMGQak7wkLE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75DD5B39-AFA3-4547-96A5-910BD24D74CA</gtr:id><gtr:title>Targeting allograft injury and inflammation in the management of post-lung transplant bronchiolitis obliterans syndrome.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bf5c6b77858a45127cf5422f70c109"><gtr:id>d1bf5c6b77858a45127cf5422f70c109</gtr:id><gtr:otherNames>Robertson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>1DF331EB155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD44496F-4822-482F-9D4B-8A09F8B13FDA</gtr:id><gtr:title>The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed30102978c38099296ea3d33e86338b"><gtr:id>ed30102978c38099296ea3d33e86338b</gtr:id><gtr:otherNames>Gardner A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>pm_13477_27_22525462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB694FB-AC9A-4E7E-B48E-B6E1B1F77D3E</gtr:id><gtr:title>Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b72897a20ce3bcbf368400ac1910dd71"><gtr:id>b72897a20ce3bcbf368400ac1910dd71</gtr:id><gtr:otherNames>Sohal SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>LyndGBCT97i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64517140-EF75-4876-B7C1-C8155C2C31E2</gtr:id><gtr:title>Nontuberculous mycobacteria in gastrostomy fed patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4206d79735212c528d84c55b562ad47"><gtr:id>f4206d79735212c528d84c55b562ad47</gtr:id><gtr:otherNames>Al-Momani H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a940325d950b0.02647032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1672B3C5-F9EE-4A0F-83B9-2CCDC4E3C84F</gtr:id><gtr:title>Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dae871136863656775086ef435066c9"><gtr:id>1dae871136863656775086ef435066c9</gtr:id><gtr:otherNames>Dhar R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>Ubt4x9j6C23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02174C31-BAFE-40E9-9982-8CB26949988A</gtr:id><gtr:title>Infection and remodelling: a 21st century model of bronchiectasis?</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f6b47377a301329abec4c2244578aa"><gtr:id>a9f6b47377a301329abec4c2244578aa</gtr:id><gtr:otherNames>Ward C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>WYjXXD2KGdg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2870244-99CE-408E-B4D9-6F1B36FE8190</gtr:id><gtr:title>Aspiration and allograft injury secondary to gastroesophageal reflux occur in the immediate post-lung transplantation period (prospective clinical trial).</gtr:title><gtr:parentPublicationTitle>Annals of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d8fcc7ebc513d1fc906dc2b1c66eabd"><gtr:id>8d8fcc7ebc513d1fc906dc2b1c66eabd</gtr:id><gtr:otherNames>Griffin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4932</gtr:issn><gtr:outcomeId>pm_13477_27_24121257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8750389E-7BF2-49BC-A165-C2629B849976</gtr:id><gtr:title>Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68394ce17788125efc5db3736789d708"><gtr:id>68394ce17788125efc5db3736789d708</gtr:id><gtr:otherNames>Murphy DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>896A2399AA0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82C209CC-E107-42C4-9703-FA90F6605E8D</gtr:id><gtr:title>Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68394ce17788125efc5db3736789d708"><gtr:id>68394ce17788125efc5db3736789d708</gtr:id><gtr:otherNames>Murphy DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn><gtr:outcomeId>AED4E024D1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D485E52F-E350-4BB2-BD62-06800AB747F7</gtr:id><gtr:title>The Potential Role of Aspiration in the Asthmatic Airway.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76aebe712539c2a6bd15c63e353eb396"><gtr:id>76aebe712539c2a6bd15c63e353eb396</gtr:id><gtr:otherNames>Hunt EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>5a940286af39f1.26377201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1CEDC73-1EE0-4985-8A1D-ACE80A333078</gtr:id><gtr:title>Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4da8d21edac913ada1d3df758b27436"><gtr:id>d4da8d21edac913ada1d3df758b27436</gtr:id><gtr:otherNames>Brodlie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>T1nXEzvzWr9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13E1F8F3-0CFA-41B0-879A-5674FAECE894</gtr:id><gtr:title>Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>mLokWwT1knR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5E34D85-46DB-4907-8E70-BB9763D4E5CC</gtr:id><gtr:title>Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4206d79735212c528d84c55b562ad47"><gtr:id>f4206d79735212c528d84c55b562ad47</gtr:id><gtr:otherNames>Al-Momani H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a9402f035b8a0.10749325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58D4E96E-D442-45BA-8B2B-7BED68B90F84</gtr:id><gtr:title>Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs.</gtr:title><gtr:parentPublicationTitle>Experimental lung research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4da8d21edac913ada1d3df758b27436"><gtr:id>d4da8d21edac913ada1d3df758b27436</gtr:id><gtr:otherNames>Brodlie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0190-2148</gtr:issn><gtr:outcomeId>HZ6ru7G3qvv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A2B7591-E233-4BF3-A4D6-C35F9EF688F6</gtr:id><gtr:title>A call for standardization of antireflux surgery in the lung transplantation population.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bf5c6b77858a45127cf5422f70c109"><gtr:id>d1bf5c6b77858a45127cf5422f70c109</gtr:id><gtr:otherNames>Robertson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>D1152B75D1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2B18AAE-1BFB-4C24-999D-AEE351FF8D76</gtr:id><gtr:title>Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b72897a20ce3bcbf368400ac1910dd71"><gtr:id>b72897a20ce3bcbf368400ac1910dd71</gtr:id><gtr:otherNames>Sohal SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>bH1ZckbkmmS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F45DCAF-8D48-480D-8B10-F6CB5E8F3FC2</gtr:id><gtr:title>Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f06925de0f6413b192dae95c9f71497d"><gtr:id>f06925de0f6413b192dae95c9f71497d</gtr:id><gtr:otherNames>Stovold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>73EB4A89A34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09F8DBD2-3D0F-4D1E-93E4-12AC36A4E59A</gtr:id><gtr:title>Susceptibility to exacerbation in COPD.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f6b47377a301329abec4c2244578aa"><gtr:id>a9f6b47377a301329abec4c2244578aa</gtr:id><gtr:otherNames>Ward C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>a47rLcePqSW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B819547-E4D7-4A5B-A9BE-4A795473DEC0</gtr:id><gtr:title>Longitudinal changes in gastro-oesophageal reflux from 3 months to 6 months after lung transplantation.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bf5c6b77858a45127cf5422f70c109"><gtr:id>d1bf5c6b77858a45127cf5422f70c109</gtr:id><gtr:otherNames>Robertson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>8247969AD05</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B2BCA47-E57F-456E-ADB0-34C1AAA18FAD</gtr:id><gtr:title>Bile acids are present in the lower airways of people with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de1e0c182abaee761d97b586fb0f8f1"><gtr:id>0de1e0c182abaee761d97b586fb0f8f1</gtr:id><gtr:otherNames>Aseeri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_13477_27_22336686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9813A59-8C79-4B1A-8517-FEFF795A39E1</gtr:id><gtr:title>Can cells other than Th17 lymphocytes be important sources of IL-17 in the lungs?</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4da8d21edac913ada1d3df758b27436"><gtr:id>d4da8d21edac913ada1d3df758b27436</gtr:id><gtr:otherNames>Brodlie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>WKkhTXi6VGu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>993AD9E1-2742-4A09-86E5-1B2D669B0BA8</gtr:id><gtr:title>Excess Mucin Impairs Subglottic Epithelial Host Defense in Mechanically Ventilated Patients.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98d3f6a700070cec4402fd593b741394"><gtr:id>98d3f6a700070cec4402fd593b741394</gtr:id><gtr:otherNames>Powell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a940242847305.22177764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596CE75B-CB81-4313-86AE-D6928A0CAA1D</gtr:id><gtr:title>From gastric aspiration to airway inflammation.</gtr:title><gtr:parentPublicationTitle>Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/467f5d1b66ea615c8aff26919767770b"><gtr:id>467f5d1b66ea615c8aff26919767770b</gtr:id><gtr:otherNames>Brownlee IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1122-0643</gtr:issn><gtr:outcomeId>F6xM4vstvDm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46A66D71-94DF-46C0-AFAE-DB63348E2781</gtr:id><gtr:title>A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/443f38a270fdefb6902c5ab027483d58"><gtr:id>443f38a270fdefb6902c5ab027483d58</gtr:id><gtr:otherNames>Corris PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>doi_55f983983abbadf2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9D9180B-4F8D-4CA8-AA38-53E68C59F840</gtr:id><gtr:title>Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bef9b0dd722a3f29d45b5ea184c9295"><gtr:id>5bef9b0dd722a3f29d45b5ea184c9295</gtr:id><gtr:otherNames>Wen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>9CE5C5C7694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DA03B2A-F407-4951-98AF-2975F228F685</gtr:id><gtr:title>TNFa from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44cc7212079edf08d8e5783c09e153a1"><gtr:id>44cc7212079edf08d8e5783c09e153a1</gtr:id><gtr:otherNames>Borthwick LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_13477_27_23331923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E15764A-09D7-48BD-B362-9D739F77BC6F</gtr:id><gtr:title>Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fecafb2c645bb4b8a053aaef178fd65"><gtr:id>3fecafb2c645bb4b8a053aaef178fd65</gtr:id><gtr:otherNames>Anwar GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn><gtr:outcomeId>2FE5953A54C</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500705</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>